drugset / Trial / NCT03021018

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

NCT03021018

Phase 2 Completed 46 enrolled UCB Biopharma S.P.R.L.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.

Timeline

Start
2017-02-06
Primary completion
2018-04-27
Completion
2018-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivaracetam Small molecule 100 mg Intravenous
Subject Brivaracetam Small molecule 200 mg Intravenous
Comparator Lorazepam Small molecule Intravenous

Indications